---
layout: default
title: Serine
parent: Model Prediction Only (L5)
nav_order: 838
evidence_level: L5
indication_count: 10
---

# Serine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Serine: From Amino Acid Nutrition Component to Familial Visceral Myopathy

## One-Sentence Summary

Serine is an amino acid that appears in Canadian parenteral nutrition products such as Travasol and Clinimix, though no approved indication text is recorded.
The TxGNN model predicts it may be effective for **familial visceral myopathy**.
**No clinical trials and no publications** currently support this prediction, so it rests on the model score alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in the Health Canada licence data |
| Predicted New Indication | Familial visceral myopathy |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 20 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Serine is marketed in Canada as part of amino acid nutrition products. Its original indication text is not recorded, so its relationship to familial visceral myopathy cannot be assessed.

The score of 0.9999 does not discriminate between candidates. The top 10 predictions all score between 0.9986 and 0.9999, and several share identical scores. Examples are the two intestinal pseudoobstruction entries, and traumatic glaucoma with aqueous misdirection. This suggests the model groups related disease nodes by graph neighbourhood rather than producing an independent signal for each. No mechanistic link between serine and this disease has been established.

The other top-10 predictions are intestinal obstruction, intestinal pseudoobstruction subtypes, neuronal intestinal dysplasia, angle-closure glaucoma, exercise-induced malignant hyperthermia, traumatic glaucoma and aqueous misdirection. None has credible supporting evidence.

- **Intestinal obstruction:** The 9 retrieved trials cover stroke, COVID-19 cardiac pathology, oncology and healthy-volunteer nutrition. None tests serine.
- **Angle-closure glaucoma:** The 11 papers concern the *PRSS56* serine protease gene, a protein class unrelated to the amino acid serine.
- **Traumatic glaucoma:** The single mTOR signalling review gives only weak, indirect context.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Canada Market Information

Dosage form and approved indication text are not recorded for these licences. Five of the 20 are listed:

| DIN | Product Name |
|---------|------|
| 872296 | TRAVASOL |
| 2498448 | CLINIMIX |
| 2498456 | CLINIMIX |
| 2498464 | CLINIMIX |
| 2510324 | ESSEPNA |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is model-only (L5), with no trials, no literature and no established mechanism. The very high score is shared across many unrelated candidates, so it carries little weight. Retrieved trials and papers for other candidate diseases are keyword-matching noise and should not raise the evidence level.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank, to test any link to visceral smooth-muscle or enteric neuromuscular disease
- Approved indication text and dosage forms for the Canadian licences
- Targeted searches for serine (the amino acid) in visceral myopathy or intestinal pseudoobstruction, excluding serine protease and serine/threonine kinase hits
- A route-compatibility assessment, which is still pending
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

